Future of antimicotic therapy;Perspektywy rozwoju terapii przeciwgrzybiczej

Mikologia Lekarska

Volumn 10, Issue 3, 2003, Pages 207-211

  Hryncewicz Gwóźdz, Anita ^a   Plomer Niezgoda, Ewa ^a   Baran, Wojciech ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Invasive fungal infections; New antifungal agents

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BIFONAZOLE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ISOCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; OXICONAZOLE; TERBINAFINE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; ASPERGILLUS; BLASTOMYCES; CANDIDA; CLINICAL TRIAL; CRYPTOCOCCUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; PENICILLIUM; REVIEW; STREPTOMYCES;

ASPERGILLUS; BLASTOMYCES; CANDIDA; PENICILLIUM; STREPTOMYCES;

EID: 0141539442     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Baran E.: Interakcje leków przeciwgrzybiczych stosowanych ogólnie z innymi grupami leków. Przegl. Mikol., 2001, 3/4, 171-174.
2. Elewski B.E.: Grzybicze zakażenia skóry. Alfa-medica press, 1998, 354-393.
3. Maleszka R., Baran E.: Lecznictwo mikologiczne w końcu dwudziestego wieku. Mikol. Lek., 2001, 1, 47-55.
4. Gallardo-Quesada S., Luelmo-Aqiular J. Guanyabens Calvet: Hepatotoxicity assitiated with itraconazole. (Letter) Int. J. Dermatol., 1995, 34, 589.
5. Gupta A.K., Katz H.I., Shear N.H.: Drug interactions with itraconazole, fluconazole and terbinafine and their management. J. Am. Acad. Dermatol., 1999, 41, 237-249.
6. Lees R.S., Lees A.M.: Rhabdomyolysis from the coadministration of lovastatin and the fungal agent itraconazole. N. Engl. J. Med., 1995, 333, 664-665.
7. McClellan K.J., Wiseman L.R., Markham A.: Terbinafine. An update of its use in superficial mycoses. Drugs, 1999, 58, 179-202.
8. Lowe G., Green C., Jennings P.: Hepatitis associated with terbinafine treatment. Br. Med. J., 1993, 306, 248.
9. Pfaller M.A., Messer S.A., Coffman S.: Comparison of visual and spectrophotometric methods for MIC endpoint detreminations by using broth microdilution methods to test five antifungal agents inclduing the new triazole DoSyo. Clin. Microbiol., 1995, 533, 1094-1097.
10. Chavez M., Bernal S., Valverde A., Gutierrez M., Quindos G., Mazuelos E.: In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents againts oral Candida sp isolates from HIV-infected patients. J. Antimicrob. Chemother., 2000, 44, 697-700.
11. Diekman D.J., Pfaller M.A., Messer S.A.: In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America. Antimicrob. Agents. Chemother., 1999, 43, 2236-2239.
12. Espinel-Ingroff A.: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (I-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol., 1998, 36, 2950-2956.
13. Cacciapuoti A., Loebenberg D., Corcoran E.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents. Chemoter., 2000, 44, 2017-2022.
14. Martin M.V., Yates J., Hitchcock C.A.: Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents. Chemother., 1997, 41, 13-16.
15. Ally R., Schurmann D., Kreisel W., Carosi G., Aguirrebengoa K., Dupont B., Hodges M., Troke P., Romero A.J.: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis., 2001, 33, 1447-1454.
16. van't Hek L.G., Verweij P.E., Weemans C.M., van Dalen R., Yntema J., Meis J.: Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am. J. Respir. Crit. Care. Med., 1998, 157, 1694-1696.
17. Tobon A.M., Arango M., Fernandez D., Restrepo A.: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posoconazole therapy. Clin. Infect. Dis., 2003, 36, 1488-1491.
18. Ernst E.J.: Investigational antifungal agents. Pharmacotherapy, 2001, 21, 165-174.
19. Ernst E.J., Klesper M., Ernst M., Messer S., Pfaller M.: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis., 1999, 33, 75-80.
20. Marco F., Pfaller M.A., Messer S.A., Jones R.N.: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida sp. Diagn. Microbiol. Infect. Dis., 1998, 32, 33-37.
21. Pfaller M.A., Jones R.N., Doern G.V.: International surveillance of bloodstream infections due to Candida species in the European SENTRY programe: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis., 1999, 35, 19-25.
22. Garbino J., Lew D., Hirschel B., Rohner P.: Caspofungin in the treatment of oropharyngeal candidiasis. Int. J. Clin. Pract., 2003, 57, 143-144.
23. Chamulean M.E., Deenik W., Zweegman S., Jonkhoff A.R., Zaaijer H.L., Janssen J.J.: Successful treatment of subcutaneous disseminated aspergillosis with caspofungin acetate in an allogenic peripheral blood stem cell transplantation patient. Hematologica, 2003, 88, ECR 10.
24. Cuenca-Estrella M., Mellado E., Diaz-Guerra T.M., Manzon A., Rodriguez-Tudela J.L.: Susceptibility of fluconazole - resistant clinical isolates of Candida spp. To echinocandin LY303366, itraconazole and amphotericin. Br. J. Antimicrob. Chemother., 2000, 46, 475-477.
25. Clemons K.V., Stevens D.A.: Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob. Agents. Chemother., 1997, 41, 2026-2028.
26. Hector R.F., Zimmer G.L., Pappagianis D.: Evaluation of nikkomycin X and Z in murine models of coccidiomycosis, histoplasmosis, and blastomycosis. Antimicrob. Agents. Chemother., 1990, 34, 587-593.
27. Dominguez J.M., Kelly V.A., Kinsman O.S., Marriott M.S., Gomez de las Heras F., Martin J.: Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents. Chemother., 1998, 42, 2274-2278.
28. Fung-Tome J.C., Minassian R., Huczko E. i wsp.: In vitro antifungal and fungicidal spectra of a new pradimicin derivative BMS-i81184. Antimicrob. Agents. Chemother., 1995, 39, 95-103.
29. Johnson E.M., Ojwang J.O., Szekely A. i wsp.: Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents. Chemother., 1998, 42, 1412-1416.
30. Ryder N.S., Letitner I.: Activity of terbinafine against Aspergillus in vitro in combination with amphotericin B or triazoles. [In:] Program and abstracts of the 6th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 54, Washington, DC, Am. Soc. Microbiol., 1996.